% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Roessling:154378,
      author       = {Roessling, Rosa and Prüß, Harald},
      title        = {{A}pheresis in {A}utoimmune {E}ncephalitis and {A}utoimmune
                      {D}ementia.},
      journal      = {Journal of Clinical Medicine},
      volume       = {9},
      number       = {9},
      issn         = {2077-0383},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DZNE-2021-00231},
      pages        = {2683},
      year         = {2020},
      note         = {ISSN 2077-0383 not unique: **3 hits**.},
      abstract     = {Autoimmune encephalitis (AE) is a rapidly progressive
                      inflammatory neurological disease. Underlying autoantibodies
                      can bind to neuronal surfaces and synaptic proteins
                      resulting in psychiatric symptoms, focal neurological signs,
                      autonomic dysfunction and cognitive decline. Early and
                      effective treatment is mandatory to reduce clinical symptoms
                      and to achieve remission. Therapeutic apheresis, involving
                      both plasma exchange (PE) and immunoadsorption (IA), can
                      rapidly remove pathogenic antibodies from the circulation,
                      thus representing an important first-line treatment in AE
                      patients. We here review the most relevant studies regarding
                      therapeutic apheresis in AE, summarizing the outcome for
                      patients and the expanding clinical spectrum of
                      treatment-responsive clinical conditions. For example,
                      patients with slowly progressing cognitive impairment
                      suggesting a neurodegenerative dementia can have underlying
                      autoantibodies and improve with therapeutic apheresis.
                      Findings are encouraging and have led to the first ongoing
                      clinical studies assessing the therapeutic effect of IA in
                      patients with anti-neuronal autoantibodies and the clinical
                      presentation of dementia. Therapeutic apheresis is an
                      established and well tolerated option for first-line therapy
                      in AE and, potentially, other antibody-mediated central
                      nervous system diseases.},
      subtyp        = {Review Article},
      keywords     = {NMDAR (N-Methyl-D-Aspartat) (Other) / antibody (Other) /
                      apheresis (Other) / autoimmune encephalitis (Other) /
                      immunoadsorption (Other) / limbic encephalitis (Other) /
                      paraneoplastic (Other) / plasma exchange (Other)},
      cin          = {AG Prüß},
      ddc          = {610},
      cid          = {I:(DE-2719)1810003},
      pnm          = {342 - Disease Mechanisms and Model Systems (POF3-342)},
      pid          = {G:(DE-HGF)POF3-342},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32824982},
      pmc          = {pmc:PMC7563270},
      doi          = {10.3390/jcm9092683},
      url          = {https://pub.dzne.de/record/154378},
}